Free Trial

Aprea Therapeutics Q2 2023 Earnings Report

Aprea Therapeutics logo
$3.08 -0.26 (-7.78%)
(As of 12/18/2024 05:44 PM ET)

Aprea Therapeutics EPS Results

Actual EPS
-$0.87
Consensus EPS
-$1.43
Beat/Miss
Beat by +$0.56
One Year Ago EPS
N/A

Aprea Therapeutics Revenue Results

Actual Revenue
$0.25 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Aprea Therapeutics Announcement Details

Quarter
Q2 2023
Time
N/A

Conference Call Resources

Forbes rich list released… #1 to be assassinated? (Ad)

Elon Musk has just exposed the “energy grift” of America in a recent tweet to his platform, X. And people are slowly starting to wake up to the Deep State’s lies.

To get the full details on the fake “energy crisis” of America, watch this now

Aprea Therapeutics Earnings Headlines

Aprea Therapeutics (NASDAQ:APRE) Receives "Buy" Rating from HC Wainwright
Promising Clinical Advances Drive Buy Rating for Aprea Therapeutics
Why I'm telling friends to avoid gold stocks
Back in November, gold made a tiny move of 1.6%. But according to my backtesting by using a special type of gold trade, I would have seen a 141% gain in just a week. It happened again in March. Gold nudged up 1.2%. This time? A 104% overnight gain. And in June? A 1% gold move turned into a 74% gain in two weeks. Granted, there would have been smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now. There's a more lucrative way to play the gold market as we enter a new breakout period. It's all about catching what I call "Acceleration Cycles."
See More Aprea Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Aprea Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aprea Therapeutics and other key companies, straight to your email.

About Aprea Therapeutics

Aprea Therapeutics (NASDAQ:APRE), a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.

View Aprea Therapeutics Profile

More Earnings Resources from MarketBeat

Upcoming Earnings